Background-The optimal management of low gradient "severe" aortic stenosis (mean gradient
Aortic stenosis (AS) has a long asymptomatic period, but once symptoms appear the outcome is dismal, if treated medically.
1 However, as symptoms of AS may be caused by other common comorbidities in the elderly, the assessment of disease severity plays an essential role in the current guidelines for aortic valve replacement (AVR). 2 Severe AS is defined as an aortic valve area (AVA) 1 cm 2 and/or indexed AVA 0.6cm 2 /m 2 and a mean transvalvular gradient (MG) 40 mmHg based on Doppler echocardiography. 3 However, treatment allocation and prediction of survival are difficult when discrepancies occur between AVA and MG.
Low gradient "severe" AS (LGSAS) is widely recognized in patients with reduced LVEF, but recent observations emphasize that LGSAS can be encountered in patients with preserved LVEF. 4, 5 This can be characterized by either reduced stroke volume -low-flow (LF-
LGSAS) -or normal flow (NF-LGSAS), both of which can lead to inconsistent grading of AS. 6 This in turn may lead to avoidance of possible AVR, especially as the gradient may be perceived as being not much greater than that of a prosthetic valve. However, while some studies have suggested that LGSAS may have more advanced disease and a worse prognosis if treated medically, 4, 7, 8 others have have suggested that the outcome of LGSAS is similar to moderate AS, 9 and shown no association of SVi with outcome. 10 To date, there are no randomized data to test potential clinical benefits of AVR in LGSAS. A recent observational study showed AVR to be associated with better survival in the paradoxical low-flow group, 11 but did not address patient selection for AVR or the normal flow subgroup. A recently-released guideline recommends AVR for LGSAS as class 2a indication (evidence level C). 12 We sought to compare the outcome of LGSAS patients who underwent AVR with those who received medical therapy.
Methods

Patient selection
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Clinical evaluation
All 260 patients with LG severe AS underwent a comprehensive medical history and physical examination. Angina was classified by Canadian Cardiovascular Society classification, dyspnea was evaluated by New York Heart Association (NYHA) class and history of syncope was sought carefully. Demographic data including age, gender, body mass index (BMI), body surface area (BSA) and comprehensive clinical data including history of hypertension, diabetes mellitus, dyslipidemia, history of smoking, coronary artery disease, peripheral arterial disease, history of prior myocardial infarction and coronary artery bypass surgery were collected. The current medications of these patients were recorded.
Systolic and diastolic blood pressures were measured at the time of echocardiographic exam and mean arterial pressure (MAP) was calculated. Society of Thoracic Surgery (STS) scores were calculated by using online risk calculator.
(http://riskcalc.sts.org/STSWebRiskCalc273/)
Echocardiographic assessment
Clinical evaluation
All 260 patients with LG severe AS underwent a comprehensive medical history and physical ex xam am amin in in t at atio io ion. n n Ang ng ngi in ina was classified by Canadian n n C Ca ardiovascular So S S ci iet et et n n n y y y classification, dyspnea A comprehensive baseline transthoracic echocardiogram (TTE) including standard M-mode, 2-dimensional, color Doppler and pulsed-wave and continuous-wave Doppler were performed using commercially available systems. LV dimensions, volumes and ejection fraction (using the biplane Simpson method), fractional shortening, LV mass and relative wall thickness (RWT)
were calculated in accordance with the current recommendations (3). LV mass was indexed to BSA and LV hypertrophy was defined as LV mass index >115 g / m 2 in men and >95 g/ m 2 in women. LV mid wall fractional shortening (MWFS) was also calculated from the formula;
MWFS= 100 x [(LVIDd/2+PWTd/2)-(LVIDs/2+PWTs/2)]/ (LVIDd/2+PWTd/2), in which LVID is left ventricular internal diameter and PWT is posterior wall thickness. Biplane LA volumes were measured from apical 2-and 4-chamber views and indexed to the BSA.
A comprehensive diastolic examination was completed using Doppler echocardiography:
diastolic dysfunction was graded as; grade 1(impaired relaxation), grade 2 (pseudo normal) and grade 3 (restrictive filling) and E/e' was calculated from the septal mitral annulus. 13 Right ventricular systolic pressure (RVSP) was estimated from tricuspid regurgitation velocity.
The maximal and mean pressure gradients were obtained using the modified Bernoulli equation. The stroke volume was calculated as the product of the cross-sectional area of the left ventricular outflow tract (LVOT) and the time-velocity integral in the LVOT. Cardiac output (CO) was calculated by multiplying HR by SV per minute. SV was indexed to the BSA and lowflow (LF) was defined as SVi<35 ml/m² (4). AVA was calculated from the continuity equation and indexed to the BSA. An average of at least 3 different measurements was used. Associated valvular abnormalities were evaluated by current guidelines and severe MR/MS and severe AI cases were excluded. 3 Global after load was estimated by valvulo-arterial impedance (Zva) which was volumes were measured from apical 2-and 4-chamber views and indexed to the e B B BSA SA S . .
A comprehensive diastolic examination was completed using Doppler echocardiography: r di ias as sto to toli li lic c dy dy dysf sf sfun unct ct cti io ion n was graded as; grade 1(im mpa pa p ir r red relaxation), ), ), gra ade de de 2 2 (pseudo normal) and g grad d de e 3 (restric icti ti tive ve e f fil il illi l n ng ng) ) ) an an nd d d E/ E/e' e' e w was as cal lcu cu culate ed from om m th the e s se sep pt tal l l m mit it itra ral l an an nnu n nulu lus. s. s. 13 13 13 R Rig i i ht ht ht ve vent nt n ri ri ricu cu c la lar r r sy sy syst sto ol lic c c p pr re ess ss sur ure (R (R (RVS VS VSP) P) P w w was as s e e es s st tim ma mate te ed d fr from om om t t tri r ricu u usp sp s id id re re regu gu urg g git itat at atio io on n n v ve vel lo loci i ity y y. .
The ma ma maxi xi x ma ma mal l an an and d me me mean a a p p pre re r ss ss ssur ur re e e gr gr grad ad adie ie i nt nt nts s s we we were re o o obt bt btai ai aine ne ned d d us s sin in ing g g th th the e e mo mo modi di difi fi fied ed ed B B Bernoulli calculated using previously defined formula Zva= (SBP+MG)/SVi, where SAP is systolic arterial pressure, MG is the mean transvalvular pressure gradient and SVi is stroke volume index. 14 Systemic vascular resistance (SVR) was estimated by the formula, SVR = (80xMAP)/CO, where MAP is the mean arterial pressure and CO is the cardiac output.
14 Systemic arterial compliance (SAC) was estimated as an indirect measurement of the ratio of SVi to brachial pulse pressure (PP). 15 Stroke work was calculated with the formula SW = (MAP+MG)xSV0.0136 and indexed to the LV mass.
Energy loss index(ELi) was also calculated by using the following formula; ELi= suggested. During the follow up period, all-cause mortality was studied in all patients by either telephone visits or using social security death index (SSDi).
Statistical analysis
Continuous data are presented as mean±standard deviation and compared with independent ttests or Mann-Whitney tests according to normality test results. Categorical variables were expressed as counts or proportions (%) and compared with a chi-square and/or Fisher's exact test accordingly.
cross-sectional area of ascending aorta at the sinotubular junction and BSA is the he e b bod od o y y y su u surf rf rfac ac a e e area in m 2 . 
Results
Patient characteristics
Based on given treatment, 260 symptomatic severe AS patients (78.4±8.6 year, 47% women) with low transvalvular mean gradient (29.1±5.3 mmHg) despite preserved LVEF (60.2±7.1%)
were divided into those who underwent AVR (94 surgical AVR and 29 transcatheter AVR) and explore the independent effect of AVR on outcome.
The Kaplan-Meier method was used to evaluate survival of those who received standard h her er rap ap apy y y vs vs s A A AV VR VR a a an nd nd to compare outcomes of NF F-F-L LGSAS and LF F-L -GS GS SA AS AS patients in an f
u una ad adjusted way ay. . U U Univ ivar aria ia iate te tely ly y s s sig ign ni nif f fic ica an ant t and d d c c clini ic ica ally y y r r rel ele ev va an ant t va va ari riab ab ble l s s we we wer re re e ent nt nter er red ed ed int nt nto o th th the e f f f f mu mu ult lt l iv iv ivar ar a ia iate te te C C Cox ox x p p pro rop po por rt rtio iona a al l ha ha haza za zard r rds s mo mo mode de dels s s i i in n o or ord der r r to to o e e exp xp xplo lo lore re e t t the he he a a ass so oci ci iat at a io io ions ns s o o of f al al ll--ca ca c us us se e mortality of g g gro ro roup up ups s s ac ac acco co cord d din in ing g g to o o t t the he heir ir i f f flo lo l w w w pa pa patt tt tter er ern. n. . A A All l s s sta ta tati ti t st st s ic ic ical al al a ana na n ly ly lyse se ses s s r r r r w w wer er re e e co co comp mp mpleted using g g those who received standard medical treatment (n=137, 53%). Decisions to undertake surgery were made at baseline evaluation.
In comparison with AVR patients, medical patients had a higher prevalence of diabetes, lower blood pressure, more prevalent diuretic use and higher creatinine level. There were no other differences in the baseline clinical profile including STS score and other demographic features ( Table 1 ).
In comparison to SAVR patients, TAVR patients were older (76±9 vs 81±9, p=0.002), more frequently female (39% vs 62%, p=0.04), and had a higher STS score (4.6±3.8 vs 10.5±4.8 %, p<0.001). However, although TAVR patients had more comorbidities with increased STS score, the length of hospital stay was shorter compared with treated by SAVR (7.7±6.2 vs 11±9 days, p=0.003). (Table 2) LV diameter, volumes, MWFS and LVEF were similar in both groups. The medical treatment group showed particularly reduced septal systolic tissue velocity (Sm) indicating decreased LV longitudinal function. Restrictive filling was also more common in medically-managed patients.
Echocardiographic and Hemodynamic Findings
Disease severity indices (i.e. area, gradients) were similar in AVR and medical groups, as was valvuloarterial impedance. AVR patients had a higher stroke volume index (36.4±8.4 ml/m 2 vs 34.4±8.7 ml/m 2 , p=0.02) and lower pulmonary artery pressure (38±11 mmHg vs 48±21 mmHg, p=0.001). Overall, 125 patients had normal flow and 135 had low-flow (SVi 35 ml/m²)
-which was present in 54 AVR patients (44%) and in 81 (59%) medically-treated patients (p=0.018).
In comparison to NF patients, LF patients were characterized by lower LVEF (62±7 vs 59±7%, p<0.0001), lower MWFS (23.4±8 vs 21±8%, p=0.002) more severe AS (0.46±0.06 vs core, the length of hospital stay was shorter compared with treated by SAVR (7. 7. .7± 7± ±6 6.2 2 2 vs vs vs 1 1 11 1± 1±9 days, p=0.003). (Table 2 ongitudinal f f fun un unct ct tio io ion. n n R R Res e tr tr tric ic cti t ve ve ve fi fill ll llin ing g g wa wa was s s al al a so so so m m mor or o e co co comm mm mmon on on i in n me me medi di dica ca call ll l y-y-ma ma mana na nage ge ged patients. Unadjusted comparison of survival (Figure 2) showed AVR as to be associated with a more favorable outcome (log rank p<0.0001). Moreover, these findings were consistent across tertiles of likelihood for undergoing surgery,as defined by the propensity score. The trend of allcause mortality across levels of risk in AVR vs medical patients was significant (p<0.0001), and there were pair-wise differences in survival between AVR and medical (p<0.0001), survival by propensity level (p=0.0008), and AVR by propensity level (p<0.0001).
Ec Echo ho hoca ca card rd rdio io iog g grap p ph hi hic c and Hemodynamic Findin n ngs gs
The associations of mortality were sought in Cox proportional hazards models (Table 3) . 
Discussion
The main findings of the present study are that AVR is independently associated with better outcome in LGSAS, and that the magnitude of benefit of AVR is not associated with stroke volume.
Low gradient severe AS with preserved EF
Low gradient "severe" AS in the setting of preserved LVEF can be divided into subgroups with reduced and preserved stroke volume. 
D Disc c scussion
Th Th he e e ma ma main in f f fin in ind di ding ng ngs s of of t the he e p pre ese se s nt nt nt s s stu tu tudy dy y a a are re re t t tha ha hat t t A AVR VR VR i i is s in in inde de depe pe end nd nden n ntl tl tly y t t t as asso soci ci ciat at ted ed e w w wi it ith be be bett tter er r has been postulated as a mechanism of having low gradient in this cohort. 18 It is important to note, however, that this group shows no difference in outcome from LF-LGSAS patients.
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The outcomes of LF-LGSAS patients were initially reported to be worse than NF patients, if treated medically, 8 reflecting more severe AS and/or less referral for AVR. However, subsequent studies have been inconsistent. 7,9,10 Jander reported a similar outcome in LGSAS and moderate AS, with no difference between LF and NF. 9 The absence of survival benefit in those who underwent AVR in that study might be related to the presence of moderate AS 19 and/or the asymptomatic status of the study population.
20
Effect of AVR on mortality
Since the gradients in LGSAS are already low, the concern is often expressed that successful AVR may show relatively less benefit than in patients with higher gradients. Clearly, the outcomes of LGSAS are an important consideration in evaluating the possible benefit of AVR, but this literature is complicated by the heterogeneity in the definition of LGSAS despite and calculated AVA in NF-LGSAS. Inconsistency between cutoff values of curre re ent nt t gui ui uide de deli li line ne n s s has been postulated as a mechanism of having low gradient in this cohort. 18 It is important to no ote te e, , ho ho howe we weve ve v r r, t tha ha hat t this group shows no differenc nc nce i in outcome fro ro om m LF LF F-L -L -LGSAS patients.
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The ou utc tcom om omes es of f f LF LF LF-L -L -LG GS GSAS AS AS p p pat t tient t ts w wer re e i init t tia ia all lly y y re e epo por rte ed ed t to o b be e w w wor or rse se t t tha ha han n n NF NF NF pa pati ti tien en nts ts t , , , if if f t t tre r reat ate ed ed m me ed dic ic cal ally y, , 8 r ref ef efle le lec ct ctin in ng g mo mo more re s s sev ev ver er re e AS AS AS a a and nd nd/o /o /or r l les es ss s s re re efe e err rral al al f f for or o A A AV V VR. . H Ho Howe we ev ve er, r ubsequent s stu tu udi di d es es s h h hav av ve e e bee ee een n n in n nco co cons ns nsis i te te tent nt nt. preserved LVEF, as well as differences in the study population (Table 4 ). In most of the studies of LGSAS, AVR has been associated with better outcome. 4, 7, 8, 21 In a retrospective analysis of 102 mainly symptomatic patients with LGSAS, AVR was found to be significantly associated with improved survival [(HR: 0.24 95%CI (0.12-0.47), p<0.001], with no survival difference between LF-LGSAS and NF-LGSAS (p=0.47). 10 These findings regarding LF and NF are similar to the retrospective analysis reported by Hachicha. 4 Our study confirms these findings in a prospectively evaluated and more homogeneous cohort with propensity analysis.
In a recent analysis comparing outcome of LF-LGSAS with moderate AS patients and high gradient severe AS patients using propensity matching based on hemodynamic criteria revealed that LF-LGSAS patients had a 1.71 fold and 2.01 fold increase in all-cause and cardiovascular mortality, respectively. Although NF LG "severe" AS patients are generally considered as a measurement error or a product of inconsistent grading of AS by current cutoff values, it is important to note that almost half of LGSAS patients are characterized by normal flow. In this regard, our unique data doesn't only confirm the observations of previous publications about LF, but also extends these observations to patients with NF.
Limitations
Although this is a prospective series, treatment assignment was not randomized -for this reason, a propensity score was created in order to explore the independent effects of treatment. In this regard, this study should be considered as hypothesis generating, but although further studies are evealed that LF-LGSAS patients had a 1.71 fold and 2.01 fold increase in all-cau au use e e and nd nd cardiovascular mortality, respectively. . U U Unf nfor ortu u una nate e ely ly ly, 18 18 186 6 6 NF NF F-L -L -LG G GSA AS AS p p pa at atie e ent nts s s w we were re re n n not ot i i inc nc n l lu lud de ded d d in in in t the he e a a ana nal ly lys si sis. s.
Although NF F LG LG
LG "se se seve ve v re r r " AS AS AS p p pat at atie ie ent n n s s ar ar are e e ge ge gene ne nera ra all ll ly y y c con on nsi si side de dere re ed d d as a a a a m m mea ea easu su sure re r me me ment nt n e e err rr r or or a needed for conclusive statements, it seems unlikely that a randomized trial could ever be done in these symptomatic patients.
Some confounding variables such as frailty, severe COPD, dementia which might have played a role in the treatment decision might have contributed to the high mortality in the medical arm. Because of limited numbers of patients undergoing TAVR, we were not able to further evaluate which AVR technique would be associated with better outcome in this setting.
Such an analysis may be important, as the performance of TAVR without need of cardiopulmonary arrest may be of particular help in LGSAS patients, who have advanced disease with multiple comorbidities.
Conclusion
In a patient with LGSAS, encountering discrepant echo results with regard to disease severity makes clinical decision-making more challenging, especially in symptomatic patients. The results of this study indicate that, if LGSAS is confirmed after excluding possible measurement errors, AVR is associated with better survival, irrespective of the flow pattern.
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